Clinical trial
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck…
NCT00401323 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00401323 |
|---|---|
| Title | Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
| Official title | A Randomized Phase II-III Multicenter Trial of Docetaxel Plus Cisplatin and Docetaxel Plus 5-FU Versus Cisplatin Plus 5-FU in 1st Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU) |
| Enrollment | 568 |
| Start date | Jan 1, 1998 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Nov 20, 2006 |
| Last update posted | Jan 20, 2011 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Guadeloupe, Hungary, Israel and 8 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: